Compare Citius Pharmaceuticals Inc (CTXR) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs United States Natural Gas Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while United States Natural Gas Fund trades at $11.12 (market cap $517.27M). The key difference: United States Natural Gas Fund is far larger — about 38× Citius Pharmaceuticals Inc's market cap, and United States Natural Gas Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and United States Natural Gas Fund for 22 Days on average.
| CTXR | UNG | |
|---|---|---|
Market Cap | $13.62M | $517.27M |
Volume | 132,438 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $1.82 | $16.90 |
52-Week Low | $0.48 | $9.63 |
Typical Hold Time | 16 Days | 22 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
UNG trades at $11.06, up 0.28% with a bullish technical signal from moving averages. The fund reported $65.15M net income for 2024 despite zero revenue, with strong total assets of $790.02M and minimal debt. Recent news highlights natural gas market volatility with record production and geopolitical tensions influencing energy prices.
The outlook is mixed: technical strength and clean balance sheet support stability, but zero revenue and negative cash flow (-$251.70M) pose fundamental risks. Investors face exposure to natural gas price swings and supply-demand imbalances, requiring careful monitoring of energy market developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
